Artículo

Type 2 diabetes: Prescription patterns and treatment outcomes of IDMPS survey in Argentina

Gagliardino, Juan Jose Icon; Elgart, Jorge Federico Icon; Forti, Luján ; Querzoli, Ivanna ; Chantelot, Jean Marc

Otros responsables

Fecha

07/2019

Editorial

Elsevier Ireland

Revista

Diabetes Research and Clinical Practice

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0168-8227

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Aim To assess prescription patterns for treatment of type 2 diabetes (T2D) and their outcomes in the IDMPS survey in Argentina. Methods Data from 2551 people with T2D recruited from 210 physicians participating in IDMPS surveys in Argentina (2006 to 2012 waves) were recorded, including medical history, medications, glycemic control, blood pressure, and lipid status. Results Most people were treated with oral glucose-lowering drugs (OGLDs) (65%), followed by combinations of these drugs plus insulin (22%) and only insulin (13%). These percentages varied according to T2D duration, the frequency of OGLDs decreasing while contrastingly and only insulin increasing (under 5 years versus over 10 years of disease duration, respectively). Average systolic blood pressure (SBP), HbA1c and LDL-c were significantly higher in patients treated with insulin either alone or associated with OGLDs. The percentage of people at target values for these parameters was also lower in these two groups. The percentage of people that reached simultaneous goal treatment values for BP, HbA1c and LDL-c levels was markedly low. Conclusion Prescription patterns for treatment of T2D follows a chronological trend and the percentage of people at goal values (HbA1c, BP and LDL-c values) was significantly lower in people receiving insulin. These data must be carefully considered by health and academic authorities in order to implement effective strategies to modify this situation.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa